Response rates in a key group shrink from 62% to 39% as the company blames a “clerical error”.
ApexOnco Front Page
Recent articles
What similarly acting projects are still unpartnered?
But toxicity could hold back Destiny-Breast06's ability to change clinical practice.
Meanwhile, Lilly gets in on the next-gen KRAS action.
Gilead came out swinging in second-line lung cancer, but it might have just whiffed.
But will the FDA accept the surrogate endpoint used in ASC4First?
Paloma-3 data suggest subcutaneous Rybrevant might have an edge over the intravenous formulation.
The PD-1 x VEGF bispecific apparently bests Keytruda, but questions remain.
